Submission of non applicability of Annual Secretarial Compliance Report for the year ended 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals has informed BSE that the Annual Secretarial Compliance Report for the financial year ended 31 March 2025 is not applicable to the company. Under SEBI LODR Regulation 15(2), the secretarial compliance requirement (Regulation 24A) does not apply to listed entities whose paid-up equity share capital is not more than Rs. 10 crore and whose net worth is not more than Rs. 25 crore as on the last day of the previous financial year. The company confirms it qualifies for this exemption on both counts. The filing is a routine regulatory disclosure submitted on 30 May 2025 under Scrip Code 536565. There is no change in business operations, financials, or governance structure disclosed.
This is a routine compliance exemption filing with no direct impact on shareholders or stock price. However, it indirectly signals that the company is small in scale — paid-up equity capital under Rs. 10 crore and net worth under Rs. 25 crore — which is useful context for investors assessing the size and maturity of the company.